menu Search
Treviamet

Treviamet

metformin + sitagliptin

Manufacturer:

Baroque Pharmaceuticals

Distributor:

Getz Pharma
Concise Prescribing Info Full Prescribing Info Contents Description Indications/Uses Dosage/Direction for Use Overdosage Contraindications Special Precautions Use In Pregnancy & Lactation Adverse Reactions Drug Interactions Storage MIMS Class ATC Classification Regulatory Classification Presentation/Packing
Concise Prescribing Info
Contents
Per 500 mg/50 mg FC tab Metformin HCl 500 mg, sitagliptin 50 mg. Per 1 g/50 mg FC tab Metformin HCl 1,000 mg, sitagliptin 50 mg
Indications/Uses
Type 2 DM in adults who are not responding to their maximal tolerated dose of metformin alone or already receiving treatment w/ a combination of sitagliptin & metformin as supplement to diet & exercise to improve glycaemic control. In conjunction w/ a sulphonylurea (ie, triple combination treatment) as addition to diet & exercise in individuals who are not satisfactorily managed on their maximal tolerated dose of both metformin & a sulphonylurea. Triple combination therapy along w/ PPARγ agonist (thiazolidinedione) in individuals not getting enough exercise or food.
Click to view Treviamet detailed prescribing information
Dosage/Direction for Use
Individualized dose taken bid. Max recommended daily dose: Metformin HCl 2,000 mg & sitagliptin 100 mg. Patient not currently treated w/ metformin Initially 500 mg/50 mg bid w/ gradual dose escalation. Patient already receiving metformin Sitagliptin 50 mg bid + dose of metformin already being taken. Patient receiving metformin 850 mg bid Initially 1,000 mg/50 mg bid.
Click to view Treviamet detailed prescribing information
Overdosage
View Treviamet overdosage for action to be taken in the event of an overdose.
Administration
Should be taken with food.
Contraindications
History of severe hypersensitivity reactions. Severe kidney impairment (eGFR <30 mL/min/1.73 m2). Metabolic acidosis eg, diabetic ketoacidosis.
Click to view Treviamet detailed prescribing information
Special Precautions
Immediately stop treatment if pancreatitis is suspected or if bullous pemphigoid is detected. Caution in patients w/ known heart failure risk factors. Evaluate renal function before starting treatment & at least once a yr thereafter. Metformin may cause vit B12 levels to drop; measure vit B12 every 2-3 yr & hematologic parameters once a yr. Increased risk of hypoglycemia w/ insulin &/or insulin secretagogue. Post-marketing reports of acute pancreatitis; acute renal failure; severe allergic reactions; incapacitating arthritis; bullous pemphigoid. Should not be used in patients w/ hepatic impairment. Inform premenopausal women about possibility of unintentional pregnancy. Evaluate renal function in elderly more often.
Click to view Treviamet detailed prescribing information
Use In Pregnancy & Lactation
Click to view Treviamet detailed prescribing information
Adverse Reactions
Diarrhea, URTI, & headache.
Click to view Treviamet detailed prescribing information
Drug Interactions
Carbonic anhydrase inhibitors may increase risk of lactic acidosis. Decreased metformin clearance w/ cimetidine, ranolazine, vandetanib, & dolutegravir. Alcohol may enhance metformin's impact on lactate metabolism.
Click to view Treviamet detailed prescribing information
Storage
View Treviamet storage conditions for details to ensure optimal shelf-life.
Description
View Treviamet description for details of the chemical structure and excipients (inactive components).
MIMS Class
Antidiabetic Agents
ATC Classification
A10BD07 - metformin and sitagliptin ; Belongs to the class of combinations of oral blood glucose lowering drugs. Used in the treatment of diabetes.
Regulatory Classification
Rx
Presentation/Packing
Form
Treviamet 1 g/50 mg FC tab
Packing/Price
100's (P2,999/box)
Form
Treviamet 500 mg/50 mg FC tab
Packing/Price
100's (P2,999/box)